

Acta Ophthalmologica

Retinal vascular function in asymptomatic individuals with a positive family history of cardiovascular disease

Journal:	<i>Acta Ophthalmologica</i>
Manuscript ID	ACTA-18-02-0157.R1
Wiley - Manuscript type:	Original Article
Date Submitted by the Author:	13-Mar-2018
Complete List of Authors:	Seshadri, Swathi ; Aston university, Optometry Karimzad , Said; Aston university, Optometry Shokr , Hala; Aston university, Optometry Gherghel, Doina; Aston university, Optometry
Keywords:	Vascular function, dynamic retinal vessel analysis, family history, cardiovascular risk

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Retinal vascular function in asymptomatic individuals with a positive family history of cardiovascular disease

Swathi Seshadri, Said E Karimzad, Hala Shokr, Doina Gherghel*

Vascular Research Laboratory, School of Life and Health Sciences, Aston University,
Birmingham UK

*Corresponding author: Dr Doina Gherghel, Aston University, Birmingham, UK.

Email:d.gherghel@aston.ac.uk. Tel: 0121 204 4120 Fax: 0121 204 4220

Abstract**Purpose:**

To compare retinal microvascular function in healthy individuals with and without a positive FH of CVD.

Methods:

Retinal vessel reactivity was assessed by means of dynamic retinal vessel analysis (DVA) in 38 healthy subjects aged between 30 and 66 years with a positive family history (FH) of cardiovascular disease (CVD), and 37 age- and gender-matched control subjects. Other assessments included blood pressure (BP) profiles, blood glucose and lipid metabolism markers, Framingham risk scores (FRS), carotid intima-media thickness (c-IMT) and brachial flow-mediated dilation (FMD).

Results:

FH positive subjects showed decreased retinal arterial baseline diameter fluctuation, dilation amplitude, percent dilation, and overall constriction response slope ($p = 0.001$; $p = 0.015$; $p = 0.001$; and $p < 0.001$, respectively), and increased percent constriction ($p = 0.008$). On the venous side, baseline corrected flicker response and dilation response slope were decreased in the FH positive group ($p = 0.009$ and $p = 0.010$, respectively). There were no significant differences between groups in c-IMT scores or FMD parameters (all $p > 0.05$). The arterial MC% correlated negatively with decreased HDL-c ($r = -0.52$, $p = 0.002$ in only FH positive group).

Conclusion:

Although macrovascular function is preserved in individuals with FH positive for CVD but with low FRS, there are, however, functional impairments at the retinal microvascular level that correlate with established plasma markers for cardiovascular risk.

Key words: Vascular function, dynamic retinal vessel analysis, family history, cardiovascular risk

INTRODUCTION

It has been previously documented that a positive family history (FH) of cardiovascular disease (CVD) increases the risk for various circulatory pathologies (Myers et al.1990; Shea et al. 1984; Khaleghi et al. 2014; Philips et al. 2007). In addition, as FH encompasses a complex interaction between environmental and genetic variables, it represents a good way of measuring the inherited component of any disease, including CVD (Banerjee 2012). Several risk scores, including the Prospective Cardiovascular Münster (PROCAM), QRISK and Scottish Intercollegiate Guidelines Network (ASSIGN) include various components of FH of CVD but due to lack of standardisation, this information is inconsistently used as a risk predictor in clinical practice. Moreover, these scores have been shown to either over- or underestimate the actual risk in a large number of individuals (Vasan 2006; Cohn 2013; Koenig 2007).

Consequently, the need arose for developing other simple tests that are quick and sensitive enough to detect subclinical disease (Wang 2011; Helfand et al.2011; Ge & Wang 2012) For this purpose, one of the most promising avenues is assessing endothelial dysfunction (ED), an entity in which the homeostatic functions of the endothelium are impaired, resulting in abnormal vascular tone, blood flow, immune cell and platelet activity/adhesion (Moncada et al. 1991).

It is well known that ED represents an early predictor of subsequent cardiovascular events or mortality. Moreover, signs of ED may be apparent even in people without an overt disease but with a FH of cardiovascular pathology (Celermajer et al.1994; Vita et al 1990; de Jongh et al.2002). Assessing this parameter is, therefore, important for predicting CVD risk and employing all the necessary preventive and therapeutic measures to decrease morbidity and mortality. Traditionally, the presence of ED is assessed by techniques such as ultrasound flow-mediated dilation (FMD), pulse wave analysis (PWA), plethysmography, and iontophoresis (Ray et al. 2014). These tests however, can be complex, time-consuming, and are performed only in highly specialized services. Dynamic retinal vessel analysis (DVA) represents a non-invasive way of evaluating VED at the retinal microvascular level (Pemp et al. 2009; Dorner et al.2003) and its usefulness in measuring early changes that signal risk for future cardiovascular pathologies in individuals with or without overt disease has already been proven (Pemp et al. 2009; Reimann et al.2009; Kotliar et al. 2011). In addition, it can also detect signs of ED at the retinal microvascular level in the presence of more subtle risk factors for CVD such as ageing

1
2
3 (Seshadri et al. 2015), ethnicity (Patel et al.2011), altered lipid and oxidative stress marker levels
4
5 (Seshadri et al. 2015), and impaired glucose tolerance (Patel et al.2012).
6
7

8
9 There is still a debate if ED can be considered an independent risk factor for CVD in low-risk
10 individuals (Cardona et al. 2015) Therefore, it is possible that ED's capabilities to predict risk for
11 CVD can be increased by association with other traditional risk factors, such as FH. Therefore,
12 this study investigates if individuals with low personal risk (FRS \leq 10%) but with FH of CVD
13 exhibit early signs of vascular dysfunction at microvascular levels when compared to those
14 without FH. In addition, the relationship between these changes and the circulatory markers for
15 CVD risk is also analysed.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Study participants

Community-dwelling volunteers (aged above 18 years) were recruited through local advertisements at the Vascular Research Laboratory and Health Clinics at Aston University (Birmingham, UK). Ethical approval for this study was received from Aston University's ethics committee and written informed consent was received from all participants prior to study enrolment. All study procedures were designed and conducted in accordance with the tenets of the Declaration of Helsinki.

Study participants were considered for inclusion on the basis of self-declared FH of CVD (to include coronary artery disease, heart failure, arrhythmia, and vascular disease) in a first-degree relative, identified by way of self-report questionnaire.

Study exclusion criteria were defined as subject history or current diagnosis of cardiovascular or cerebrovascular disease including coronary artery disease, heart failure, arrhythmia, stroke, transient ischemic attacks, peripheral vascular disease, as well as, hypertension, diabetes, and or severe dyslipidemia (defined as plasma triglyceride levels > 6 mmol/L or cholesterol levels > 7 mmol/L). Smoking and the use of vasoactive medications, such as dietary supplements containing vitamins or antioxidants and bronchodilators, also served as exclusion criteria for the study participants. In addition, potential subjects were screened for ocular diseases and were excluded from if they had a refractive error of more than ± 3 DS and more than ± 1 DC equivalent, elevated intraocular pressures (> 21 mmHg), retinal disease, intraocular surgery, neuro-ophthalmic disease, cataract, or other media opacities that may affect the ocular vascular system or prevent retinal vascular examination.

General assessments

All study-related measurements were performed between 8 and 11 AM following a 12-hour overnight fast, which included refraining from alcohol or caffeine. Standard anthropometric measures of height and weight were recorded to determine body mass index (BMI = weight/height²). Systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) were measured using an automatic BP monitor (UA-767; A&D Instruments Ltd, UK) to determine mean arterial pressure (MAP = 2/3 DBP + 1/3 SBP). Intraocular pressure (IOP) was measured using non-contact tonometry (Pulsair; Keeler Ltd, UK) to determine ocular perfusion pressure (OPP = 2/3 MAP – IOP). In addition, blood and plasma samples drawn from the antecubital fossa vein were assessed immediately for fasting glucose (GLUC), triglycerides (TG), total cholesterol (CHOL), and high-density lipoprotein cholesterol (HDL-c) using the Reflotron Desktop Analyzer (Roche Diagnostics, UK). Low-density lipoprotein cholesterol (LDL-c) values were calculated as per the Friedewald equation (Friedewald et al. 1972).

Cardiovascular risk scores for each subject were also calculated using the current version of the Framingham risk score (FRS) published by an expert panel of the National Heart, Lung and Blood Institute (NHLBI 2002), which includes the following risk factors: age, sex, CHOL, HDL-c, SBP, treatment for hypertension, smoking status, and diabetes. Age, sex, treatment for hypertension, smoking, and the presence of diabetes were identified from self-report questionnaires, whereas CHOL, HDL-c, and SBP values were as those determined on the day of study. The risk scoring algorithm is based on gender-specific points assigned for each risk factor variable. Ten-year risk percentage was then calculated based on total points (1 point, 6%; 2 points, 8%; 3 points, 10%; 4 points, 12%; 5 points, 16%; 6 points, 20%; 7 points, 25%; 10 points or more, > 30%). Finally, the absolute CVD risk percentage was classified as low risk (< 10%), intermediate risk (10-20%), or high risk (> 20%) (Ford et al. 2004). Only those individuals classified in the low-risk category were considered for this study.

Vascular assessments

Carotid intima-media thickness measurements of the common carotid arteries (c-IMT) were obtained for all participants, as described previously (Seshadri et al. 2015), and in accordance with an already published protocol (Salonen et al. 1991). Briefly, with the subject in supine position, a high-resolution B-mode ultrasound system (Siemens, Acuson-Sequoia, UK) was used to capture an image of the right then left carotid artery at the level of the carotid bifurcation. Measurements of the thickness of the inner two layers of the artery were then taken from the central region of the inferior arterial wall at a site proximal to the artery bifurcation using the instrument's in-built software caliper system.

Flow-mediated dilation (FMD) of the brachial artery was determined using a high-resolution ultrasound imaging system with a 7 mm 8MHz linear-array (Siemens; Acuson-Sequoia, UK). The brachial artery was imaged above the antecubital fossa in a longitudinal plane. A segment with clear anterior and posterior intimal interfaces between the lumen and vessel wall was selected for continuous 2D grey-scale imaging. The vessel diameter, from the anterior to the posterior interface between the media and adventitia, was then continually measured using a specialized, artificial neural networking, wall-detection software (VIA[®] Software, UK). According to a published protocol (Corretti et al. 2002), a baseline image of the artery was first acquired. The brachial artery was then temporarily occluded by BP cuff inflated 50 mmHg above each individual's SBP for a standardized five minutes. Image recording was then continued for an additional two minutes following cuff deflation. Endothelium-dependent FMD (FMD_{ED}) was expressed as a percentage of the maximal artery dilation during hyperemia (MD_{hyperemia}) relative to the average vessel diameter recorded during the 2-minute baseline image acquisition (AD_{baseline}).

Dynamic retinal vessel analysis (DVA) was carried out using the retinal vessel analyzer system (IMEDOS; GmbH, Jena, Germany). All measurements were performed in one unselected eye following full pupil dilation with Tropicamide 1% (Chauvin Pharmaceuticals Ltd, UK), and in a quiet, temperature-controlled room (22°C). A visual fixation target was used to control eye movements and to position the region of interest at the center of the fundus image. Within this region, a segment approximately 0.5 to 1 mm and 1 to 2 disc diameters from the optic nerve head

1
2
3 was selected for continual diameter recording, for both the inferior temporal retinal artery and
4 retinal vein. Arterial and venous vessel diameters were then assessed simultaneously and
5 continuously over 350 seconds, according to an accepted and widely used protocol (Nagel et al.
6 2006). In short, the whole vessel diameter measurement duration (350 seconds) consists of a 50-
7 second baseline measurement followed by continual diameter recordings during three
8 consecutive 100-second flicker cycles, each comprised of 20 seconds of flickering light
9 (stimulus) interrupted by 80 seconds of still illumination (recovery). Visualization plots to
10 evaluate the dynamic nature of the vessels' response profiles were created by extracting the raw
11 response data from the device software and applying a statistical polynomial regression
12 algorithm using MATLAB (Mathworks, USA) according to a method perfected in-house
13 (Mroczkowska et al. 2012) The following retinal vessel reactivity and time course parameters
14 were then calculated for both the artery and the vein (Heitmar et al. 2010). The differences
15 between maximum and minimum baseline vessel diameter was termed as baseline-diameter
16 fluctuation (BDF), the maximum diameter (MD) was used to describe the maximal vessel
17 dilation in response to flicker-light stimulation expressed as a percentage relative to baseline, the
18 time taken (seconds) to reach the maximum vessel diameter during the twenty-second flicker
19 exposure was termed as MD reaction time (tMD), the minimal vessel diameter within thirty
20 seconds of the recovery period was calculated as a percentage relative to baseline and expressed
21 as the maximum constriction (MC) whilst the time taken (seconds) to reach maximal vessel
22 constriction was termed maximum constriction reaction time (tMC), and finally, the difference
23 between maximal dilation and constriction responses was termed as the dilation amplitude (DA).
24 More recently, an additional parameter was introduced by our research group that can be used
25 describe the change in vessel diameter as a function of time (slope) and can be calculated for the
26 dilation ($\text{Slope}_D = (\text{MD} - \text{baseline}) / \text{tMD}$) and constriction components ($\text{Slope}_C = (\text{MC} -$
27 $\text{baseline}) / \text{tMC}$) of the vessel response profile (Mroczkowska et al. 2012).

28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 **Statistical analysis**

48
49
50 All statistical analyses were performed using Statistica[®] software (Version 9, StatSoft Inc, USA).
51 The Shapiro-Wilk test was used to determine the distribution of the data. Multivariate analysis
52 was used to test the influence of age, BMI, BP, circulating markers, and systemic parameters on
53 the measured variables. Differences between groups were subsequently assessed using
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

independent sample *t*-tests or ANCOVA, as appropriate. Within-group correlations between retinal vascular reactivity and systemic parameters were explored using Pearson's or Spearman's rank method, as appropriate. A *p*-value of less than 0.05 was considered significant, except in certain cases where a stricter *p*-value of less than 0.01 was adopted in order to correct for multiple comparisons.

What is described in the results section is RESULTS

In total, 102 participants were screened for eligibility of which 27 were excluded on the basis of having moderate or high FRS scores (>10%) or if the quality of the DVA recording was below the acceptable quality control. The remaining 75 healthy subjects were then classified into one of two groups based on the self-declared presence or absence of CVD in a first-degree relative (FH positive: $n = 38$, controls: $n = 37$, respectively). The number of participants in each group was similar (Chi-square $p = 0.909$) as was the within-group distributions of male (M) and female (F) participants (FH positive: M = 20; F = 18, Control: M = 22, F = 15, Chi-square $p = 0.551$).

Clinical characteristics

A summary of the clinical and systemic vascular characteristics of the FH positive and control subjects is presented in Table 1. There were no significant group differences in age, BMI, SBP, DBP, HR, MAP, IOP, OPP, GLUC, TG, CHOL, LDL-c, TG: HDL-c, and FRS (all $p > 0.05$). However, in comparison to controls, FH positive subjects exhibited lower levels of HDL-c ($p = 0.030$) and higher CHOL: HDL-C ratios ($p = 0.021$).

Systemic vascular parameters

After correcting for all the possible influences identified through the multivariate analyses, there were no significant group differences in c-IMT scores brachial AD_{baseline} , $MD_{\text{hyperaemia}}$, or FMD_{ED} (all $p > 0.05$ ANCOVA, Table 1)

Retinal vascular parameters

Arterial response. After controlling for influential covariates in ANCOVA models, statistically significant differences in arterial BDF ($p = 0.001$), MD% ($p = 0.001$), MC% ($p = 0.008$), and Slope_{AC} ($p < 0.001$) (Fig. 1 A) were identified between the two study groups (Table 2). No significant group differences in any of the other measured arterial DVA parameters were identified (all $p > 0.05$).

Venous response. After controlling for influential covariates in ANCOVA models as appropriate, group comparisons showed statistically lower venous BCFR ($p = 0.009$) and dilation

1
2
3 response Slope_{VD} ($p = 0.010$) in the FH positive group in comparison to controls (Table 2; Fig.
4 1B). No significant group differences in any of the other measured venous DVA parameters were
5 identified (all $p > 0.05$).
6
7

8 9 **Correlations between microvascular retinal function and systemic parameters**

10
11 In the FH positive group, increased arterial MC% was associated with decreased HDL-c ($r = -$
12 0.52 , $p = 0.002$, Fig. 2). A similar trend could not be observed in the control group ($p > 0.05$). No
13 other significant correlations were identified in either of the study groups ($p > 0.05$).
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

This study has demonstrated that independent of systemic influences, early signs of microvascular dysfunction are detectable at the retinal arterial and venous levels of otherwise healthy subjects with a positive FH for CVD, even when the macrovascular structure and function (as assessed by c-IMT and FMD measurements) are within normal limits. These changes correlated with established plasma markers for cardiovascular risk.

Firstly, spontaneous variations in baseline diameters before the onset of flicker (BDF) were found to be reduced in the FH positive subjects in comparison to controls. We can hypothesize that this observation is the result of an imbalance in the adaptive mechanism that enables a healthy vessel to adjust its baseline diameters to an increased metabolic demand after flickering stimulation (Kotliar et al. 2004; Vilser et al. 2002; Kotliar et al. 2011). In addition, a reduction in arterial dilation and over-constrictions post-flicker were also observed in individuals with positive FH as compared to controls. It is possible that the participants with a positive FH for CVD, although otherwise healthy, displayed some limitations in the functional vascular reserves that may only be evident after provocative stressors showing that increased challenges cannot be met. In addition, we also observed that FH positive subjects demonstrated a decreased retinal venous dilation response slope, a composite parameter that could reflect a decrease in retinal venous dilation diameter and/or a delay in reaching maximal dilation diameter. Although retinal veins are thought to play a more passive role in autoregulatory function (Kotliar et al. 2004) we could speculate that the functional changes observed at both arterial and venous levels could signal key generalised microvascular alterations associated with the presence of non-modifiable risk factors, such as FH. It is possible that such limitation in the retinal vascular function are inherited and will predispose individuals with a positive FH to CVD later in life.

Our observations of abnormal retinal microvascular responses in this category of individuals is in line with previous studies reporting reduced coronary blood flow (Schachinger et al. 1999) and skin reactive hyperemia in otherwise healthy subjects with FH of hypertension (Maver et al. 2004) or diabetes (Lee et al. 2011). Moreover, previous studies have also demonstrated that an impaired microvascular endothelial function may be evident as early as adolescence in those with a FH of cardiovascular disease (de Jongh et al. 2002). Indeed, poor microvessel function

1
2
3 represents an inherited phenotype for CVD risk in patients with familial risk factors (Noon et al.
4 1997; Barrett-Connor et al. 1984; Colditz et al. 1986; Marenberg et al. 1994; Friedlander et al.
5 1985; Grech et al. 1992).

6
7
8 However, beside genetic factors, other mechanisms could also be contributing to the two above-
9 mentioned pathological entities (Martino et al. 2015) of circulatory function. Longitudinal, more
10 complex studies are, therefore, required to understand the relative importance of our observations
11 in FH positive individuals. From our experience, in individuals with low CVD risk, retinal
12 microvascular function can be affected by various factors such as ethnicity (Patel et al. 2011) and
13 ageing (Seshadri et al. 2015a). In addition, we have also published that body's antioxidant
14 capacity is also linked to the vascular function as measured at the microvascular retinal level
15 (Seshadri et al. 2015b). This later observation is very important and could offer us a possible
16 explanation for the present findings. Indeed, it has been independently shown that individuals
17 with a positive FH for CVD display higher levels of oxidative stress than the normal population
18 (Kelishadi et al. 2009). Although the levels of antioxidant molecules were not determined and
19 compared in this study, it can be hypothesized that this factor could have contributed to our
20 findings.
21
22
23
24
25
26
27
28
29
30

31
32 Our study also found a favourable relationship between high HDL-C level and microvascular
33 function at the retinal arterial level. Indeed, subjects without a positive family history of CVD
34 had higher HDL-C levels than those with positive FH and in the latter category, the abnormal
35 HDL-C level was associated with an abnormal vascular constriction response. It has been
36 previously shown that high levels of HDL-C do not only offer protection against atherosclerosis
37 but also predicts a favourable course of symptomatic vascular disease (Kim et al. 2014).
38 Therefore, our study comes to confirm the necessity of treating low HDL-C levels in individuals
39 without overt CVD but with risk factors such as history of premature CHD (<50 years old in a
40 first-degree relative) (Link et al. 2007).
41
42
43
44
45
46
47
48
49

50 In conclusion, the results of the present study show that familial risk for CVD is associated with
51 alterations in retinal vascular function that correlate with circulating markers for CVD risk. With
52 traditional cardiovascular risk scoring systems such as the FRS known to severely underestimate
53 relative risk (Vasan 2006; Cohn 2013) the findings of the present study suggest that functional
54
55
56
57
58
59
60

1
2
3 retinal assessments can provide an improved diagnostic capability for the detection of subclinical
4 microvascular dysfunction. This approach could be promising in furthering the concept of early
5 vascular screening and prevention strategies, an important step towards the development of
6 individualized and targeted endothelial therapies that can improve the life-time risk in
7 individuals that were traditionally considered low-risk (Chia 2016).
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

Banerjee A (2012). A review of family history of cardiovascular disease: risk factor and research tool. *International journal of clinical practice* **66**, 536-543.

Barrett-Connor E & Khaw K (1984) . Family history of heart attack as an independent predictor of death due to cardiovascular disease. *Circulation* **69**, 1065-1069 .

Cohn JN (2013): Identifying the risk and preventing the consequences of cardiovascular disease. *Heart, lung & circulation* **22**, 512-516.

Celermajer DS, Sorensen K E, Bull C, Robinson J & Deanfield J E (1994): Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. *Journal of the American College of Cardiology* **24**, 1468-1474 .

Cardona A, Kondapally SSR, Davey J, Arrebola-Moreno AL, Ambrosio G, Kaski JC & Ray KK (2015): A meta-analysis of published studies of endothelial dysfunction does not support its routine clinical use. *International journal of clinical practice* **69**, 649-658.

Corretti MC, Anderson TJ, Benjamin EJ et al (2002): Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. *Journal of the American College of Cardiology* **39**, 257-265.

Colditz GA, Stampfer MJ, Willett WC, Rosner B, Speizer FE & Hennekens CH(1986): A prospective study of parental history of myocardial infarction and coronary heart disease in women. *American journal of epidemiology* **123**, 48-58 .

Chia Y SY, 04-4 (2016): How to improve CVD risk prediction in a low-risk population. *Journal of hypertension* **34**, e16 .

1
2
3 De Jongh S, Lilien MR, Bakker HD, Hutten BA, Kastelein JJ & Stroes ES (2002): Family
4 history of cardiovascular events and endothelial dysfunction in children with familial
5 hypercholesterolemia. *Atherosclerosis* **163**, 193-197.
6
7

8
9
10 Dorner GT, Garhofer G, Kiss B, Polska E, Polak K, Riva CE & Schmetterer L (2003): Nitric
11 oxide regulates retinal vascular tone in humans. *American Journal of Physiology-Heart and*
12 *Circulatory Physiology* **285**, H631-H636.
13
14
15

16
17 Friedewald WT, Levy R & Fredrickson DS (1972): Estimation of the concentration of low-
18 density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clinical*
19 *chemistry* **18**, 499-502.
20
21
22

23
24 Ford ES, Giles WH & Mokdad AH (2004): The distribution of 10-Year risk for coronary heart
25 disease among US adults: findings from the National Health and Nutrition Examination Survey
26 III. *Journal of the American College of Cardiology* **43**, 1791-1796 .
27
28
29

30
31 Friedlander Y, Kark JD & Stein Y (1985): Family history of myocardial infarction as an
32 independent risk factor for coronary heart disease. *British heart journal* **53**, 382-387.
33
34
35

36 Ge Y & Wang TJ (2012): Identifying novel biomarkers for cardiovascular disease risk
37 prediction. *Journal of internal medicine* **272**, 430-439.
38
39
40

41 Grech ED, Ramsdale DR, Bray CL & Faragher EB (1992): Family history as an independent risk
42 factor of coronary artery disease. *European heart journal* **13**, 1311-1315 .
43
44
45

46 Helfand M, Buckley DI, Freeman M, Fu R, Rogers K, Fleming C, Humphrey LL (2009):
47 Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for
48 the U.S. Preventive Services Task Force. *Annals of internal medicine* **151**, 496-507.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Heitmar R, Blann A D, Cubbidge RP , Lip GY & Gherghel D (2010): Continuous retinal vessel
4 diameter measurements: the future in retinal vessel assessment? *Investigative ophthalmology &*
5 *visual science* **51**, 5833-5839.
6
7

8
9
10 Khaleghi M, Isseh IN, Bailey KR & Kullo IJ (2014): Family history as a risk factor for
11 peripheral arterial disease. *The American journal of cardiology* **114**, 928-932.
12
13

14
15 Koenig W (2007): Cardiovascular biomarkers: added value with an integrated approach?
16 *Circulation* **116**, 3-5.
17
18

19
20 Kotliar KE , Lanzl IM, Schmidt-Trucksäss A, Sitnikova D, Ali M, Blume K, Halle M & Hanssen
21 H (2011): Dynamic retinal vessel response to flicker in obesity: *A methodological approach.*
22 *Microvascular research* **81**, 123-128.
23
24

25
26
27 Kotliar KE, Vilser W, Nagel E & Lanzl IM (2004): Retinal vessel reaction in response to
28 chromatic flickering light. *Graefes Arch Clin Exp Ophthalmol* **242**, 377-392.
29
30

31
32 Kelishadi R, Sabri M, Motamedi N & Ramezani MA (2009): Factor analysis of markers of
33 inflammation and oxidation and echocardiographic findings in children with a positive family
34 history of premature coronary heart disease. *Pediatric cardiology* **30**, 477-481.
35
36
37

38
39 Kim BJ , Hong KS, Cho YJ, et al (2014): Predictors of symptomatic and asymptomatic
40 intracranial atherosclerosis: what is different and why? *Journal of atherosclerosis and*
41 *thrombosis* **21**, 605-617.
42
43
44

45
46 Lee BC, Shore AC, Humphreys JM, Lowe GD, Rumley A, Clark PM, Hattersley AT & Tooke
47 JE (2001): Skin microvascular vasodilatory capacity in offspring of two parents with Type 2
48 diabetes. *Diabetic medicine : a journal of the British Diabetic Association* **18**, 541-545 (2001).
49
50
51

52
53 Link JJ, Rohatgi A & de Lemos JA. (2007): HDL cholesterol:physiology,pathophysiology, and
54 management. *Current problems in cardiology* **32**, 268-314 .
55
56
57
58
59
60

1
2
3
4
5 Myers RH, Kiely DK, Cupples LA & Kannel WB (1990): Parental history is an independent risk
6 factor for coronary artery disease: the Framingham Study. *American heart journal* **120**: 963-969
7

8
9
10 Moncada S, Palmer R & Higgs E (1991): Nitric oxide: physiology, pathophysiology, and
11 pharmacology. *Pharmacological reviews* **43**, 109-142 .
12

13
14
15 Mroczkowska S, Ekart A, Sung V et al (2012): Coexistence of macro- and micro-vascular
16 abnormalities in newly diagnosed normal tension glaucoma patients. *Acta ophthalmologica* **90**,
17 e553-559.
18

19
20
21
22 Maver J, Struel M & Accetto R (2004): Autonomic nervous system and microvascular
23 alterations in normotensives with a family history of hypertension. *Blood pressure* **13**, 95-100 .
24

25
26
27
28
29 Marenberg ME, Risch N, Berkman LF, Floderus B & de Faire U (1994): Genetic susceptibility
30 to death from coronary heart disease in a study of twins. *The New England journal of medicine*
31 **330**, 1041-1046.
32

33
34
35
36 Martino F, Magenta A, Barilla F (2016): Epigenetics and cardiovascular risk in childhood.
37 *Journal of Cardiovascular Medicine* **17**, 539-546.
38

39
40
41 Nagel E, Vilser W, Fink A & Riemer T (2006): Variance of retinal vessel diameter response to
42 flicker light. A methodical clinical study. *Der Ophthalmologe : Zeitschrift der Deutschen*
43 *Ophthalmologischen Gesellschaft* **103**, 114-119.
44

45
46
47
48 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation,
49 and Treatment of High Blood Cholesterol in Adults (2002): Third Report of the National
50 Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment
51 of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* **106**,
52 3143-3421.
53
54
55
56
57
58
59
60

1
2
3
4
5 Noon JP, Walker BR, Webb DJ, Shore AC, Holton DW, Edwards HV & Watt GC(1997):
6 Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition
7 to high blood pressure. *The Journal of clinical investigation* **99**, 1873-1879.
8
9

10
11 Philips B, de Lemos JA, Patel MJ, McGuire DK & Khera A (2007). Relation of family history of
12 myocardial infarction and the presence of coronary arterial calcium in various age and risk factor
13 groups. *The American journal of cardiology* **99**.
14
15
16
17
18
19

20 Pemp B , Weigert G, Karl K, Petzl U, Wolzt M, Schmetterer L & Garhofer G (2009): Correlation
21 of flicker-induced and flow-mediated vasodilatation in patients with endothelial dysfunction and
22 healthy volunteers. *Diabetes care* **32**, 1536-1541.
23
24
25
26

27 Patel SR, Bellary S, Qin L, Gill PS, Taheri S, Heitmar R, Gibson JM & Gherghel D (2011):
28 Abnormal retinal vascular function and lipid levels in a sample of healthy UK South Asians. *The*
29 *British journal of ophthalmology* **95**, 1573-1576.
30
31
32
33

34 Patel SR, Bellary S, Qin L, Balanos GM, McIntyre D & Gherghel D (2012): Abnormal retinal
35 vascular reactivity in individuals with impaired glucose tolerance: a preliminary study.
36 *Investigative ophthalmology & visual science* **53**, 5102-5108 .
37
38
39
40

41 Ray S, Miglio C, Eden T & Del Rio D (2014): Assessment of vascular and endothelial
42 dysfunction in nutritional studies. *Nutr Metab Cardiovasc Dis* **24**, 940-946.
43
44
45

46 Reimann M , Prieur S, Lippold B, Bornstein SR, Reichmann H, Julius U & Ziemssen T(2009):
47 Retinal vessel analysis in hypercholesterolemic patients before and after LDL apheresis.
48 *Atheroscler Suppl* **10**, 39-43.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Shea S, Ottman R, Gabrieli C, Stein Z & Nichols A (1984): Family history as an independent
4 risk factor for coronary artery disease. *Journal of the American College of Cardiology* **4**, 793-
5 801.
6
7

8
9
10 Seshadri S, Ekart A & Gherghel D (2015)a: Ageing effect on flicker-induced diameter changes
11 in retinal microvessels of healthy individuals. *Acta ophthalmologica*.
12

13
14
15 Seshadri S, Mroczkowska S, Qin L, Patel S, Ekart A & Gherghel D (2015)b: Systemic circulatory
16 influences on retinal microvascular function in middle-age individuals with low to moderate
17 cardiovascular risk. *Acta ophthalmologica* **93**, e266-274.
18
19

20
21
22 Salonen R, Haapanen A & Salonen JT (1991): Measurement of intima-media thickness of
23 common carotid arteries with high-resolution B-mode ultrasonography: inter- and intra-observer
24 variability. *Ultrasound in medicine & biology* **17**, 225-230.
25
26

27
28
29 Schächinger V, Britten MB, Elsner M, Walter DH, Scharrer I & Zeiher AM (1999): A positive
30 family history of premature coronary artery disease is associated with impaired endothelium-
31 dependent coronary blood flow regulation. *Circulation* **100**, 1502-1508.
32
33

34
35
36 Vasan RS (2006): Biomarkers of cardiovascular disease: molecular basis and practical
37 considerations. *Circulation* **113**, 2335-2362.
38
39

40
41 Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn
42 AP & Ganz P (1990): Coronary vasomotor response to acetylcholine relates to risk factors for
43 coronary artery disease. *Circulation* **81**, 491-497.
44
45

46
47
48 Vilser W, Nagel E & Lanzl I (2002): Retinal Vessel Analysis--new possibilities. *Biomedizinische*
49 *Technik. Biomedical engineering* **47 Suppl 1 Pt 2**, 682-685 .
50
51


Figure Legends

Figure 1. Group comparisons of retinal vascular response profiles.


(A) Arterial response, (B) Venous response. Abbreviations: AU, arbitrary units; BDF, baseline diameter fluctuation; BCFR, baseline corrected flicker response; FH, family history; MD%, percent dilation; MC%, percent constriction; Slope_{AC}, arterial constriction slope; Slope_{VD}, venous dilation slope.


Figure 2. Correlation between HDL-c and retinal arterial percent constriction in the FH positive group.

Abbreviations: FH, Family history; HDL-c, high-density lipoprotein cholesterol; MC%, percent constriction.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Clinical and systemic vascular characteristics

Variable	Mean (SD)		<i>p</i> -value	Significance
	FH positive (1)	Control (2)		
N	38	37	0.909	-
Gender	20M : 18F	22M : 15F	0.551	-
Age (years)	47 (11)	45 (11)	0.468	-
BMI (kg/m ²)	27.13 (4.45)	26.75 (4.72)	0.727	-
SBP (mmHg)	121 (11)	121 (12)	0.752	-
DBP (mmHg)	74 (9)	76 (9)	0.227	-
HR (bpm)	65 (10)	68 (8)	0.096	-
MAP	89.36 (8.90)	91.29 (9.05)	0.356	-
IOP (mmHg)	14 (2)	14 (3)	0.439	-
OPP	45.15 (6.36)	46.91 (5.54)	0.206	-
GLUC (mmol/L)	4.95 (1.07)	5.08 (0.58)	0.539	-
TG (mmol/L)	1.14 (0.44)	1.15 (0.62)	0.958	-
CHOL (mmol/L)	4.68 (1.02)	4.55 (0.98)	0.578	-
HDL-C (mmol/L)	1.16 (0.41)*	1.39 (0.45)	0.030*	1 < 2
LDL-C (mmol/L)	3.00 (0.97)	2.67 (0.92)	0.156	-
TG/HDL-c	1.11 (0.56)	1.00 (0.84)	0.515	-
CHOL/HDL-c	4.39 (1.36)*	3.61 (1.36)	0.021*	1 > 2
FRS %	5.91 (4.16)	4.85 (3.78)	0.105	-
c-IMT	0.55 (0.11)	0.58 (0.11)	0.318	-
AD _{baseline} (mm)	4.16 (0.93)	4.44 (0.88)	0.174	-
MD _{hyperaemia} (mm)	4.61 (1.12)	5.14 (1.26)	0.060	-
FMD _{ED}	10.88 (9.42)	12.13 (8.63)	0.520	-

Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; MAP, mean arterial pressure; IOP, intraocular pressure; OPP, ocular perfusion pressure; GLUC, glucose; TG, triglycerides; CHOL, total cholesterol; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; FRS%, Framingham risk score; c-IMT, carotid intima media thickness; AD_{baseline}, brachial baseline diameter; MD_{hyperaemia}, maximum brachial diameter during hyperaemia; FMD_{ED}, endothelium-dependent flow-mediated dilation. * Significant *p*-values are indicated in bold where *p* < 0.05 was considered

Table 1. Group differences in retinal vascular reactivity parameters

DVA parameter	Mean (SD)		p-value (t-test/ANCOVA)	Significance
	FH positive (1)	Control (2)		
<i>Arteries:</i>				
Baseline	100.02 (0.05)	100.01 (0.06)	0.552	-
BDF	5.13 (2.10)	6.50 (2.88)	0.001*	1 < 2
BCFR	1.04 (2.00)	1.12 (3.07)	0.882	-
DA	6.16 (2.67)	7.51 (2.76)	0.015	-
MD%	3.74 (2.25)	5.22 (2.50)	0.001*	1 < 2
MC%	-2.42 (1.87)	-2.29 (2.31)	0.008*	1 > 2
tMD (seconds)	19 (6)	22 (8)	0.048	-
tMC(seconds)	29 (6)	26 (8)	0.064	-
Slope _{AD}	0.24 (0.12)	0.30 (0.15)	0.070	-
Slope _{AC}	-0.25 (0.13)	-0.38 (0.25)	<0.001*	1 < 2
<i>Veins:</i>				
Baseline	100.00 (0.04)	100.00 (0.03)	0.775	-
BDF	3.94 (1.78)	3.79 (1.68)	0.011	-
BCFR	1.40 (2.42)	2.35 (1.83)	0.009*	1 < 2
DA	5.33 (2.91)	6.09 (2.60)	0.242	-
MD%	4.44 (2.74)	5.43 (2.38)	0.045	-
MC%	-0.90 (1.59)	-0.66 (1.04)	0.461	-
tMD (seconds)	21 (6)	20 (4)	0.200	-
tMC (seconds)	28 (7)	31 (8)	0.058	-
Slope _{VD}	0.23 (0.13)	0.29 (0.12)	0.010*	1 < 2
Slope _{VC}	-0.23 (0.16)	-0.23 (0.14)	0.960	-

Abbreviations: Baseline, average baseline diameter; BDF, baseline diameter fluctuation; DA, dilation amplitude; BCFR, baseline corrected flicker response; MD%, percent dilation (during flicker); MC%, percent constriction (post-flicker); tMD, time taken to reach maximal dilation (MD) diameter; tMC, time taken to reach maximal constriction (MC) diameter; Slope_{AD/VD}, slope of arterial/venous dilation; Slope_{AC/VC}, slope of arterial/venous constriction. *Significant p-values are indicated in bold where $p < 0.01$ was considered significant